Provided are compounds for treating and/or preventing obesity and obesity-related disorders. Particularly, provided are chromanone derivatives used as ATF3 inducer and for treating and/or preventing obesity and obesity-related disorders such as heart disease, hypertension, hyperlipidemia and diabetes.